- Raised $20M Series B led by Mylan, May 2020
- Raised $10M convertible note led by Zhejiang Sanhua Co, Oct 2018
- Raised $10M Series A led by Shavit Capital Fund, Apr 2015
About
Mapi Pharma is a clinical-stage pharmaceutical company focused on developing proprietary pharmaceuticals, including life cycle management (LCM) products such as long-acting depot injections, complex active pharmaceutical ingredients (APIs), and formulations. The company aims to meet unmet patient needs with innovative long-acting treatments, particularly for multiple sclerosis, and has a strong pipeline of products. Mapi Pharma is headquartered in Ness Ziona, Israel, with R&D facilities in Israel and China, an API production facility in the Neot-Hovav Eco Industrial Park, and a sterile manufacturing and fill & finish facility for injectable Finished Dosage Forms in Jerusalem. Mapi Pharma utilizes extended-release depot technologies protected by strong intellectual property to develop lifecycle management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The company has established collaborations with industry leaders like Mylan/Viatris.
Funding history · 4 rounds · $42.5M total
Headcount over time
Q&A
- What is Mapi Pharma's primary focus?
- Mapi Pharma is a clinical-stage pharmaceutical company that develops proprietary pharmaceuticals, including long-acting depot injectable treatments and complex active pharmaceutical ingredients.
- When was Mapi Pharma founded?
- Mapi Pharma was founded in 2008.
- How many employees does Mapi Pharma currently have?
- Mapi Pharma has 51–200 employees.
- What was the outcome of Mapi Pharma's GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS)?
- In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS).
- Did Mapi Pharma receive any patents recently?
- In March 2022, Mapi Pharma received a U.S. Patent covering methods of suppressing or alleviating primary or secondary progressive multiple sclerosis with a sustained-release Glatiramer Acetate Depot.
- Has Mapi Pharma established any distribution agreements in the UAE?
- In October 2021, Mapi Pharma signed an agreement with Gaelan Medical Trade LLC to exclusively market and distribute Mapi products in the UAE.
- Who is the CEO of Mapi Pharma?
- Ehud Marom is the Co-Founder and CEO of Mapi Pharma.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mapi-pharma.com |
|---|---|
| linkedin.com/company/5229663 | |
| YouTube | youtube.com/channel/UCX1qdf5rKzaWtsUwJ_dxFVQ |
| Wikidata | wikidata.org/wiki/Q104481086 |
Identifiers & details
| Legal name | Mapi Pharma Ltd. |
|---|---|
| Founded | 2008 |
| Employees (exact) | 63 |
| Offices | Nanjing |
| Wikidata QID | Q104481086 |
Radar intelligence
Patents
| EPO | 52 |
|---|
Web history (Wayback)
| Domain | mapi-pharma.com |
|---|
Wikidata
| QID | Q104481086 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514092782 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-01-29 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 3 — shares_capital (2), annual_report (1) |
| Registered address | אינשטיין 16 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2026-03-23 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2026-03-23 | הקצאת מניות |
| 2026-03-17 | דו~ח שנתי-הקצאת מניות |